Radius Health, Inc. (NASDAQ:RDUS)‘s stock had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald in a research note issued on Friday. They currently have a $58.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 96.21% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Jefferies Group LLC reduced their price objective on Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a research note on Friday. Canaccord Genuity set a $85.00 price objective on Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $51.00.

Radius Health (NASDAQ:RDUS) traded down $1.29 during midday trading on Friday, hitting $29.56. The stock had a trading volume of 2,872,114 shares, compared to its average volume of 954,239. Radius Health has a fifty-two week low of $27.16 and a fifty-two week high of $55.97.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the prior year, the company earned ($1.07) earnings per share. sell-side analysts anticipate that Radius Health will post -5.28 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/04/radius-health-inc-rdus-receives-buy-rating-from-cantor-fitzgerald.html.

In related news, major shareholder Growth N. V. Biotech purchased 50,000 shares of Radius Health stock in a transaction that occurred on Wednesday, October 25th. The shares were purchased at an average cost of $32.85 per share, with a total value of $1,642,500.00. Following the transaction, the insider now owns 5,548,799 shares of the company’s stock, valued at approximately $182,278,047.15. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jesper Hoiland purchased 6,100 shares of Radius Health stock in a transaction that occurred on Friday, September 15th. The shares were bought at an average cost of $32.72 per share, for a total transaction of $199,592.00. Following the completion of the transaction, the insider now directly owns 6,100 shares in the company, valued at approximately $199,592. The disclosure for this purchase can be found here. Insiders have purchased a total of 519,100 shares of company stock worth $17,970,882 over the last three months. 15.00% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. increased its holdings in Radius Health by 3.1% during the 1st quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 180 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 541 shares during the last quarter. Sei Investments Co. increased its holdings in Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its holdings in Radius Health by 4.1% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 690 shares during the last quarter. Finally, California Public Employees Retirement System increased its holdings in Radius Health by 2.3% during the 2nd quarter. California Public Employees Retirement System now owns 71,600 shares of the biopharmaceutical company’s stock worth $3,238,000 after purchasing an additional 1,600 shares during the last quarter.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.